GA
ELI

Geneva Advisors’s ELITE PHARMACEUTICAL ELI Stock Holding History

Geneva Advisors’s Portfolio ELI Stock Details ELI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$75K Buy
401,252
+48,192
+14% +$9.01K ﹤0.01% 706
2017
Q1 		$52K Buy
353,060
+59,880
+20% +$8.82K ﹤0.01% 731
2016
Q4 		$45K Hold
293,180
– – ﹤0.01% 741
2016
Q3 		$52K Hold
293,180
– – ﹤0.01% 715
2016
Q2 		$95K Hold
293,180
– – ﹤0.01% 649
2016
Q1 		$91K Hold
293,180
– – ﹤0.01% 648
2015
Q4 		$120K Buy
293,180
+2,300
+0.8% +$941 ﹤0.01% 600
2015
Q3 		$67K Hold
290,880
– – ﹤0.01% 586
2015
Q2 		$58K Hold
290,880
– – ﹤0.01% 645
2015
Q1 		$71K Hold
290,880
– – ﹤0.01% 629
2014
Q4 		$66K Hold
290,880
– – ﹤0.01% 642
2014
Q3 		$93K Buy
290,880
+10,450
+4% +$3.34K ﹤0.01% 623
2014
Q2 		$119K Hold
280,430
– – ﹤0.01% 621
2014
Q1 		$115K Buy
280,430
+30,540
+12% +$12.5K ﹤0.01% 594
2013
Q4 		$30K Hold
249,890
– – ﹤0.01% 536
2013
Q3 		$31K Buy
249,890
+50,000
+25% +$6.2K ﹤0.01% 490
2013
Q2 		$14K Buy
+199,890
New +$14K ﹤0.01% 436

Other funds holding ELI

JAFL
Jay A. Fishman Ltd Troy, Michigan $1.12B AUM 32.75% 1-Year Est. Return
SBL
Sargent Bickham Lagudis Boulder, Colorado $1.22B AUM 14.94% 1-Year Est. Return

Geneva Advisors's ELI Position: Q2 2017 in Review

Geneva Advisors increased its ELITE PHARMACEUTICAL (ELI) stake by 14% in Q2 2017, buying an estimated $9.01K and bringing the position to 401,252 shares worth $75K. The position accounts for ﹤0.01% of the portfolio, ranked #706.

Geneva Advisors first reported a position in ELI in Q2 2013 and has held it in 17 quarters since. The position peaked at $120K in Q4 2015. 3 funds tracked by Wall St. Rank hold ELI as of Q2 2017.

  • Geneva Advisors held 401,252 shares of ELITE PHARMACEUTICAL worth $75K as of Q2 2017.
  • Geneva Advisors bought 48,192 ELITE PHARMACEUTICAL shares in Q2 2017, an estimated $9.01K.
  • ELITE PHARMACEUTICAL made up ﹤0.01% of Geneva Advisors's portfolio in Q2 2017, its #706 holding.
  • Geneva Advisors first reported a position in ELITE PHARMACEUTICAL in Q2 2013 and has held it in 17 quarters since.
  • Geneva Advisors's ELITE PHARMACEUTICAL position peaked at $120K in Q4 2015.
  • 3 funds tracked by Wall St. Rank held ELITE PHARMACEUTICAL as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.